MBIO - Dosing underway in Mustang Bio's Phase 1 trial of MB-101 in brain tumors

The first patient has been dosed in Mustang Bio's (MBIO) Phase 1 trial to establish the safety and feasibility of administering MB-101 (autologous IL13R?2-CAR T cells) to patients with leptomeningeal brain tumors.The trial will enroll up to 30 patients. All subjects will undergo surgery for the placement of an intraventricular ((ICV)) Rickham catheter for CAR T cell delivery.MB-101 through the ICV Rickham catheter will be evaluated over four weekly cycles in patients with glioblastoma (Arm 1) and ependymoma or medulloblastoma (Arm 2).The primary endpoints are toxicity and survival at three months.Secondary endpoints include overall survival, CAR T and endogenous T cell levels, cytokine levels and phenotype detection in peripheral blood, tumor cyst fluid and cerebrospinal fluid.MBIO shares up 7.3% premarket trading at $3.07.

For further details see:

Dosing underway in Mustang Bio's Phase 1 trial of MB-101 in brain tumors